Kopran Limited (IN:KOPRAN)
:KOPRAN
Top Page
Kopran Limited
(KOPRAN)
Select Model
Select Model
Rating:57Neutral
Price Target:
₹125.00
▼(-17.87% Downside)
Action:ReiteratedDate:12/03/25
Kopran Limited's overall stock score is primarily influenced by its financial performance, which shows strong revenue growth and operational efficiency but faces challenges in cash flow conversion. Technical analysis indicates a bearish trend, and valuation metrics suggest the stock may be overvalued. The lack of earnings call and corporate events data limits further insights.
Positive Factors
Strong balance sheet
The company's high equity ratio and low leverage provide durable financial flexibility. Low debt burden reduces refinancing and interest risk, supports regulatory compliance and capex funding, and increases resilience to sector cycles over the next several quarters.
Negative Factors
Negative free cash flow
Despite positive operating cash flow, persistent negative free cash flow implies heavy capex or working capital drag, limiting internal funding for growth, dividends or debt reduction. Continued negative FCF would strain financial flexibility over 2–6 months.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong balance sheet
The company's high equity ratio and low leverage provide durable financial flexibility. Low debt burden reduces refinancing and interest risk, supports regulatory compliance and capex funding, and increases resilience to sector cycles over the next several quarters.
Read all positive factors
Kopran Limited (KOPRAN) vs. iShares MSCI India ETF (INDA)
Market Cap
₹5.82B
Dividend Yield1.96%
Average Volume (3M)13.07K
Price to Earnings (P/E)19.4
Beta (1Y)1.26
Revenue Growth-6.96%
EPS Growth-66.75%
CountryIN
Employees842
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)1.93
Shares Outstanding48,285,606
10 Day Avg. Volume27,236
30 Day Avg. Volume13,071
Financial Highlights & Ratios
PEG Ratio-0.96
Price to Book (P/B)1.74
Price to Sales (P/S)1.44
P/FCF Ratio-67.21
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Kopran Limited Business Overview & Revenue Model
Company Description
Kopran Limited, an integrated pharmaceutical company, manufactures and sells active pharmaceutical ingredients and finished dosage forms in India and internationally. The company offers its products in various dosage forms, including tablets, caps...
How the Company Makes Money
Kopran Limited makes money primarily by selling pharmaceutical products across two broad categories: (1) active pharmaceutical ingredients (APIs) and (2) finished dosage formulations (FDFs). Revenue is generated through (a) sales of APIs to other ...
Kopran Limited Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
68
Positive
Cash Flow
54
Neutral
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.92B | 6.30B | 6.15B | 5.48B | 4.74B | 4.81B |
| Gross Profit | 2.09B | 2.25B | 2.09B | 1.86B | 1.90B | 1.67B |
| EBITDA | 485.63M | 729.00M | 868.18M | 548.77M | 980.11M | 997.82M |
| Net Income | 175.99M | 385.52M | 509.56M | 272.33M | 610.31M | 616.06M |
Balance Sheet | ||||||
| Total Assets | 8.13B | 8.44B | 7.43B | 6.50B | 6.11B | 4.39B |
| Cash, Cash Equivalents and Short-Term Investments | 372.08M | 258.64M | 80.91M | 73.97M | 58.68M | 9.35M |
| Total Debt | 1.57B | 1.48B | 992.28M | 752.38M | 745.49M | 663.02M |
| Total Liabilities | 3.12B | 3.26B | 2.52B | 2.10B | 1.85B | 1.94B |
| Stockholders Equity | 5.01B | 5.18B | 4.91B | 4.39B | 4.26B | 2.45B |
Cash Flow | ||||||
| Free Cash Flow | 234.30M | -134.46M | -133.56M | -270.22M | -757.47M | 355.37M |
| Operating Cash Flow | 553.87M | 419.42M | 432.58M | 340.23M | -334.75M | 599.51M |
| Investing Cash Flow | -335.65M | -564.28M | -435.52M | -126.50M | -844.15M | -252.79M |
| Financing Cash Flow | -107.78M | 258.68M | 9.88M | -198.44M | 1.23B | -345.71M |
Kopran Limited Technical Analysis
Neutral
152.20
Price Trends
127.54
Negative
134.66
Negative
152.97
Negative
Market Momentum
-3.64
Negative
49.23
Neutral
50.88
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:KOPRAN, the sentiment is Neutral. The current price of 152.2 is above the 20-day moving average (MA) of 118.53, above the 50-day MA of 127.54, and below the 200-day MA of 152.97, indicating a neutral trend. The MACD of -3.64 indicates Negative momentum. The RSI at 49.23 is Neutral, neither overbought nor oversold. The STOCH value of 50.88 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:KOPRAN.
Kopran Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | ₹12.24B | 8.47 | ― | 0.37% | ― | ― | |
66 Neutral | ₹11.31B | 22.21 | ― | ― | 24.20% | 55.01% | |
64 Neutral | ₹8.05B | 12.53 | ― | ― | 8.92% | -5.56% | |
62 Neutral | ₹7.36B | 14.99 | ― | 1.92% | 14.09% | -34.41% | |
57 Neutral | ₹5.82B | 19.44 | ― | 1.96% | -6.96% | -66.75% | |
56 Neutral | ₹4.86B | 34.53 | ― | ― | 32.95% | 67.39% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:KOPRAN
Kopran Limited
120.50
-51.02
-29.75%
IN:KILITCH
Kilitch Drugs (India) Limited
138.95
-32.38
-18.90%
IN:LINCOLN
Lincoln Pharmaceuticals Ltd
610.85
76.42
14.30%
IN:SAKAR
Sakar Healthcare Ltd
515.30
279.26
118.31%
IN:WANBURY
Wanbury Limited
230.40
-10.75
-4.46%
IN:ANUHPHR
Anuh Pharma Limited
73.44
-7.52
-9.29%
Kopran Limited Corporate Events
Kopran Closes Trading Window Ahead of FY26 Results
Mar 24, 2026
Kopran Limited has announced the closure of its trading window for directors, designated persons and their immediate relatives from 1 April 2026 until 48 hours after the declaration of its audited financial results for the fourth quarter and full ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.